Moderna, Inc., a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced the finalization of a strategic partnership with the UK government to establish a state-of-the-art mRNA research, development, and manufacturing facility in…
Phase I trial in Rwanda and South Africa aims to evaluate mRNA HIV vaccine antigen for safety and immunogenicity and strengthen regional scientific capacity NEW YORK, NY and CAMBRIDGE, MA / ACCESSWIRE / May 18,…
CAMBRIDGE, MA / ACCESSWIRE / May 9, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that that it will host its in-person Science and Technology Day for…
On-shore manufacturing facility based in Melbourne, Australia, expected to produce up to 100 million mRNA respiratory vaccine doses annually CAMBRIDGE, MA / ACCESSWIRE / March 23, 2022 / Moderna, Inc. (NASDAQ:MRNA), a biotechnology company pioneering…
Endorsement to proceed given by the independent Data and Safety Monitoring Board based on preliminary Phase 2 safety and tolerability data Moderna expects to enroll approximately 34,000 participants in multiple countries RSV causes severe disease…
– Multivalent technology approach for seasonal influenza mRNA vaccine candidate addressing four different influenza strains – Influenza candidate developed in collaboration with GSK within broad infectious disease vaccine program TÜBINGEN, GERMANY and BOSTON, MA /…
Approval based on a comprehensive submission package including efficacy and safety data approximately six months after second dose SPIKEVAX has received approval by regulators in more than 70 countries, including Canada, Japan, the European Union,…
VANCOUVER, BC / ACCESSWIRE / January 10, 2022 / Eyam Vaccines and Immunotherapeutics is pleased to publicly announce the appointment of Elizabeth Varki Jobes and Dr. Terry Pearson to the Board of Directors, and the…
Kai Medical Laboratory is Approved to Administer the Pfizer and Janssen Vaccines and Opens COVID-19 Vaccine Drive-Through VANCOUVER, BC / ACCESSWIRE / November 8, 2021 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an…
AXON presented results from its Phase II Clinical Study for AADvac1, vaccine against Alzheimer’s presented at Eurotau2021AXON demonstrated that vaccination-induced antibodies can stop the interaction and spreading of pathological tau species and protect the brain…